BIOMARIN PHARMACEUTICAL INC. — Revenue by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3fdad5c1-66e1-4a57-bf1e-c83e18d04001/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $3.2B | 2025-01-01 – 2025-12-31 | evidence 0001048477-26-000004 |
| FY 2024 | $2.9B | 2024-01-01 – 2024-12-31 | evidence 0001048477-25-000007 |
| FY 2023 | $2.4B | 2023-01-01 – 2023-12-31 | evidence 0001048477-24-000016 |
| FY 2022 | $2.1B | 2022-01-01 – 2022-12-31 | evidence 0001048477-23-000009 |
| FY 2021 | $1.8B | 2021-01-01 – 2021-12-31 | evidence 0001048477-22-000012 |
| FY 2020 | $1.9B | 2020-01-01 – 2020-12-31 | evidence 0001048477-21-000008 |
| FY 2019 | $1.7B | 2019-01-01 – 2019-12-31 | evidence 0001048477-20-000009 |
| FY 2018 | $1.5B | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005033 |
| FY 2017 | $1.3B | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-005033 |
| FY 2016 | $1.1B | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-005033 |
| FY 2015 | $884.5M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013653 |
| FY 2014 | $738.4M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001140 |
| FY 2013 | $538.4M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-070025 |
| FY 2012 | $496.5M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-077031 |
| FY 2011 | $437.6M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-072924 |
| FY 2010 | $369.7M | 2010-01-01 – 2010-12-31 | evidence 0001193125-11-045527 |
| FY 2009 | $315.7M | 2009-01-01 – 2009-12-31 | evidence 0001193125-11-045527 |
| FY 2008 | $251.9M | 2008-01-01 – 2008-12-31 | evidence 0001193125-11-045527 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
BIOMARIN PHARMACEUTICAL INC. — all facts · Net Income · Operating Income